# Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

> **NCT02558894** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 65 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** MEDI4736 monotherapy
- **DRUG:** tremelimumab+MEDI4736

## Key facts

- **NCT ID:** NCT02558894
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-16
- **Primary completion:** 2017-06-15
- **Final completion:** 2017-06-15
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558894, "Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02558894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*